Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Lubiprostone

FDA-approved product (capsule, oral), marketed as Amitiza, Lubiprostone.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Lubiprostone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chronic pain
  • Constipation
  • Constipation disorder
  • Irritable bowel syndrome

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other drugs for constipation
FDA pharmacologic class
Chloride Channel Activator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA51.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli28.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.1% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Lubiprostone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Lubiprostone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Opioid-induced Bowel Dysfunction: Pivotal Assessment of Lubiprostone

    NCT00595946 · start 2007-08

    Registered record
    Registry ID
    NCT00595946
    Conditions
    Opioid-Induced Bowel Dysfunction
    Interventions
    Lubiprostone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-08
    Completion
    2009-03
    Enrolment
    439

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-Induced Bowel Dysfunction
    InterventionLubiprostone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Opioid-induced Bowel Dysfunction Pivotal Assessment of Lubiprostone

    NCT00597428 · start 2007-08

    Registered record
    Registry ID
    NCT00597428
    Conditions
    Opioid-Induced Bowel Dysfunction
    Interventions
    Lubiprostone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2007-08
    Completion
    2009-03
    Enrolment
    437

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOpioid-Induced Bowel Dysfunction
    InterventionLubiprostone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Safety and Efficacy of Lubiprostone in Pediatric Patients With Constipation

    NCT00452335 · start 2007-01

    Registered record
    Registry ID
    NCT00452335
    Conditions
    Constipation
    Interventions
    Lubiprostone; Lubiprostone; Lubiprostone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2007-01
    Completion
    2008-10
    Enrolment
    127

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionConstipation
    InterventionLubiprostone; Lubiprostone; Lubiprostone
    PhasePhase 4
    Registry statusCompleted

  • Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

    NCT00380250 · start 2005-05

    Registered record
    Registry ID
    NCT00380250
    Conditions
    Irritable Bowel Syndrome With Constipation
    Interventions
    Lubiprostone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-05
    Completion
    2006-07
    Enrolment
    590

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome With Constipation
    InterventionLubiprostone; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Efficacy and Safety of Lubiprostone in Patients With Irritable Bowel Syndrome With Constipation

    NCT00399542 · start 2005-05

    Registered record
    Registry ID
    NCT00399542
    Conditions
    Irritable Bowel Syndrome; Constipation
    Interventions
    Lubiprostone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-05
    Completion
    2006-07
    Enrolment
    581

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIrritable Bowel Syndrome; Constipation
    InterventionLubiprostone; Placebo
    PhasePhase 3
    Registry statusCompleted